|
業務類別
|
Biotechnology |
|
業務概覽
|
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others. |
| 公司地址
| 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158 |
| 電話號碼
| +1 415 482-5300 |
| 傳真號碼
| +1 415 339-5300 |
| 公司網頁
| https://www.nektar.com |
| 員工數量
| 61 |
| Mr. Howard W. Robin |
Director, President and Chief Executive Officer |
美元 1.08M |
25/04/2025 |
| Ms. Elizabeth Zhang |
Vice President, Legal and Corporate Counsel |
-- |
21/11/2025 |
| Dr. Jonathan Zalevsky, PhD |
Senior Vice President and Chief Research and Development Officer |
美元 703.49K |
14/03/2025 |
| Ms. Sandra A. Gardiner |
Interim Chief Financial Officer and Principal Accounting Officer |
-- |
14/03/2025 |
|
|
| Mr. Howard W. Robin |
Director, President and Chief Executive Officer |
25/04/2025 |
| Mr. Jeffrey R. Ajer |
Independent Director |
25/04/2025 |
| Mr. Roy A. Whitfield |
Lead Independent Director |
25/04/2025 |
| Mr. Robert B. Chess |
Chairman of the Board |
25/04/2025 |
| Mr. R. Scott Greer |
Independent Director |
25/04/2025 |
| Dr. Diana M. Brainard, M.D. |
Independent Director |
25/04/2025 |
|
|
|
|
